ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy.
Adult
Aged
Aged, 80 and over
Chemoradiotherapy
Cisplatin
/ administration & dosage
Disease-Free Survival
Female
Genetic Association Studies
Genotype
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Polymorphism, Single Nucleotide
/ genetics
Prognosis
Squamous Cell Carcinoma of Head and Neck
/ drug therapy
Xeroderma Pigmentosum Group D Protein
/ genetics
Journal
The pharmacogenomics journal
ISSN: 1473-1150
Titre abrégé: Pharmacogenomics J
Pays: United States
ID NLM: 101083949
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
23
06
2019
accepted:
28
05
2020
revised:
09
05
2020
pubmed:
18
6
2020
medline:
23
11
2021
entrez:
18
6
2020
Statut:
ppublish
Résumé
Identifying patients with locally advanced head and neck carcinoma on high risk of recurrence after definitive concurrent radiochemotherapy is of key importance for the selection for consolidation therapy and for individualized treatment intensification. In this multicenter study we analyzed recurrence-associated single-nucleotide polymorphisms (SNPs) in DNA repair genes in tumor DNA from 132 patients with locally advanced head and neck carcinoma (LadHnSCC). Patients were treated with definitive radiotherapy and simultaneous cisplatin-based chemotherapy at six partner sites of the German Cancer Consortium (DKTK) Radiation Oncology Group from 2005 to 2011. For validation, a group of 20 patients was available. Score selection method using proportional hazard analysis and leave-one-out cross-validation were performed to identify markers associated with outcome. The SNPs rs1799793 and rs13181 were associated with survival and the same SNPs and in addition rs17655 with freedom from loco-regional relapse (ffLRR) in the trainings datasets from all patients. The homozygote major rs1799793 genotype at the ERCC2 gene was associated with better (Hazard ratio (HR): 0.418 (0.234-0.744), p = 0.003) and the homozygote minor rs13181 genotype at ERCC2 with worse survival (HR: 2.074, 95% CI (1.177-3.658), p = 0.017) in comparison to the other genotypes. At the ffLRR endpoint, rs1799793 and rs13181 had comparable prognostic value. The rs1799793 and rs13181 genotypes passed the leave-one-out cross-validation procedure and associated with survival and ffLRR in patients with LadHnSCC treated with definitive radiochemotherapy. While findings were confirmed in a small validation dataset, further validation is underway within a prospective biomarker study of the DKTK.
Identifiants
pubmed: 32546699
doi: 10.1038/s41397-020-0174-1
pii: 10.1038/s41397-020-0174-1
pmc: PMC7840506
doi:
Substances chimiques
Xeroderma Pigmentosum Group D Protein
EC 3.6.4.12
ERCC2 protein, human
EC 5.99.-
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
37-46Commentaires et corrections
Type : ErratumIn
Références
Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35.
doi: 10.1056/NEJMoa0912217
Lacas B, Bourhis J, Overgaard J, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18:1221–37.
doi: 10.1016/S1470-2045(17)30458-8
Subramanian J, Simon R. Overfitting in prediction models—is it a problem only in high dimensions? Contemp Clin Trials. 2013;36:636–41.
doi: 10.1016/j.cct.2013.06.011
Sher DJ, Adelstein DJ, Bajaj GK, et al. Radiation therapy for oropharyngeal squamous cell carcinoma: executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol. 2017;7:246–53.
doi: 10.1016/j.prro.2017.02.002
Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 2002;62:4899–902.
pubmed: 12208738
Blasiak J. DNA-damaging anticancer drugs—a perspective for DNA repair—oriented therapy. Curr Med Chem. 2017;24:1488–503.
doi: 10.2174/0929867324666170124145557
Farnebo L, Stjernstrom A, Fredrikson M, Ansell A, Garvin S, Thunell LK. DNA repair genes XPC, XPD, XRCC1, and XRCC3 are associated with risk and survival of squamous cell carcinoma of the head and neck. DNA Repair. 2015;31:64–72.
doi: 10.1016/j.dnarep.2015.05.003
Azad AK, Bairati I, Samson E, et al. Validation of genetic sequence variants as prognostic factors in early-stage head and neck squamous cell cancer survival. Clin Cancer Res. 2012;18:196–206.
doi: 10.1158/1078-0432.CCR-11-1759
Barnett GC, Coles CE, Elliott RM, et al. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol. 2012;13:65–77.
doi: 10.1016/S1470-2045(11)70302-3
Melchardt T, Hufnagl C, Magnes T, et al. CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer. BMC Cancer. 2015;15:725.
doi: 10.1186/s12885-015-1776-x
Song X, Sturgis EM, Jin L, Wang Z, Wei Q, Li G. Variants in nucleotide excision repair core genes and susceptibility to recurrence of squamous cell carcinoma of the oropharynx. Int J Cancer. 2013;133:695–704.
doi: 10.1002/ijc.28051
Zhong S, Nukui T, Buch S, et al. Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the head and neck are treatment dependent. Cancer Epidemiol Biomark Prev. 2011;20:2429–37.
doi: 10.1158/1055-9965.EPI-11-0520
Werbrouck J, De Ruyck K, Duprez F, et al. Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys. 2009;73:1187–95.
doi: 10.1016/j.ijrobp.2008.08.073
Linge A, Lohaus F, Lock S, et al. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiother Oncol. 2016;121:364–73.
doi: 10.1016/j.radonc.2016.11.008
De-Colle C, Menegakis A, Monnich D, et al. SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. Radiother Oncol. 2018;126:125–31.
doi: 10.1016/j.radonc.2017.10.008
Lunn RM, Helzlsouer KJ, Parshad R, et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis. 2000;21:551–5.
doi: 10.1093/carcin/21.4.551
Carles J, Monzo M, Amat M, et al. Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006;66:1022–30.
doi: 10.1016/j.ijrobp.2006.06.029
Wyss AB, Weissler MC, Avery CL, et al. Single nucleotide polymorphisms in nucleotide excision repair genes, cancer treatment, and head and neck cancer survival. Cancer Causes Control. 2014;25:437–50.
doi: 10.1007/s10552-014-0346-x
Mumbrekar KD, Goutham HV, Vadhiraja BM, Bola Sadashiva SR. Polymorphisms in double strand break repair related genes influence radiosensitivity phenotype in lymphocytes from healthy individuals. DNA Repair. 2016;40:27–34.
doi: 10.1016/j.dnarep.2016.02.006
Li F, Xie X, Ren X, Zhang J. A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy. Cancer Chemother Pharmacol. 2016;77:1183–91.
doi: 10.1007/s00280-016-3015-9
Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J. The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol. 2005;34:1319–28.
doi: 10.1093/ije/dyi169
SAS Institute Inc. SAS/STAT 9.2 user’s guide. SAS Institute Inc.: Cary, NC; 2008. https://support.sas.com/en/books/authors.html .
Shriner D. Approximate and exact tests of Hardy-Weinberg equilibrium using uncertain genotypes. Genet Epidemiol. 2011;35:632–7.
doi: 10.1002/gepi.20612
Rushing C, Bulusu A, Hurwitz HI, Nixon AB, Pang H. A leave-one-out cross-validation SAS macro for the identification of markers associated with survival. Comput Biol Med. 2015;57:123–9.
doi: 10.1016/j.compbiomed.2014.11.015
Wellek S, Ziegler A. A genotype-based approach to assessing the association between single nucleotide polymorphisms. Hum Hered. 2009;67:128–39.
doi: 10.1159/000179560
Pepe MS, Fleming TR. Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data. Biometrics. 1989;45:497–507.
doi: 10.2307/2531492
Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2011;40:D930–4.
doi: 10.1093/nar/gkr917
Lopes-Aguiar L, Costa EF, Nogueira GA, et al. XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation. Oncotarget. 2017;8:16190–201.
doi: 10.18632/oncotarget.7668
Wan XC, Egloff AM, Johnson J. Histological assessment of cervical lymph node identifies patients with head and neck squamous cell carcinoma (HNSCC): who would benefit from chemoradiation after surgery? Laryngoscope. 2012;122:2712–22.
doi: 10.1002/lary.23572
Zhang G, Guan Y, Zhao Y, et al. ERCC2/XPD Lys751Gln alter DNA repair efficiency of platinum-induced DNA damage through P53 pathway. Chem Biol Interact. 2017;263:55–65.
doi: 10.1016/j.cbi.2016.12.015
Li S-X, Dai Q-S, Chen S-X, et al. Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis. Tumour Biol. 2014;35:3905–15.
doi: 10.1007/s13277-013-1519-z
Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Res. 2016;44:D877–81.
doi: 10.1093/nar/gkv1340
Moisan F, Laroche-Clary A, Auzanneau C, et al. Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity. Carcinogenesis. 2012;33:962–8.
doi: 10.1093/carcin/bgs107
Gao WM, Romkes M, Day RD, et al. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer. Carcinogenesis. 2003;24:1671–6.
doi: 10.1093/carcin/bgg115
Yu SN, Liu GF, Li XF, Fu BH, Dong LX, Zhang SH. Evaluation of prediction of polymorphisms of DNA repair genes on the efficacy of platinum-based chemotherapy in patients with non-small cell lung cancer: a network meta-analysis. J Cell Biochem. 2017;118:4782–91.
doi: 10.1002/jcb.26147
Yang Y, Xian L. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumor Biol. 2014;35:2905–21.
doi: 10.1007/s13277-013-1493-5
van Huis-Tanja L, Kweekel D, Gelderblom H, et al. Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples. Pharmacogenomics. 2013;14:2005–12.
doi: 10.2217/pgs.13.169
Van Allen EM, Mouw KW, Kim P, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014;4:1140–53.
doi: 10.1158/2159-8290.CD-14-0623